Clinical Trial: A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma

U.S., July 3 -- ClinicalTrials.gov registry received information related to the study (NCT07682272) titled 'A Trial of SHR-8068 Combined With Adebrelimab and Apatinib in Perioperative Treatment of Resectable Hepatocellular Carcinoma' on June 26.

Brief Summary: This study is conducted to evaluate the efficacy and safety of SHR-8068 combined with Adebrelimab and Apatinib compared with Adebrelimab combined with Apatinib in perioperative treatment of resectable hepatocellular carcinoma with intermediate or high recurrence risk.

Study Start Date: July, 2026

Study Type: INTERVENTIONAL

Condition: Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk

Intervention: DRUG: SHR-8068 Injection

SHR-8068 injection.

DRUG: A...